Cue biopharma's lead clinical asset, cue-101, to be featured at the 2024 multi-disciplinary head and neck cancers symposium

Boston, feb. 29, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific t cells, announced today that the company's lead clinical asset, cue-101, will be featured in a presentation at the 2024 multi-disciplinary head and neck cancers symposium given by alexander dimitrios colevas, m.d., a principal investigator at stanford university participating in the cue-101 clinical trial. the symposium is being held in phoenix, arizona and virtually from february 29 – march 2, 2024.
CUE Ratings Summary
CUE Quant Ranking